Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Mar 30, 2020 3:59pm
310 Views
Post# 30861498

RE:RE:The health care system is overwhelmed with work

RE:RE:The health care system is overwhelmed with work Get in before the HALT in am announcing study and monitoring is completed and anaysis in underway.........
qwerty22 wrote:

In one way or another the role of hospitals in this process is pretty much behind us, worst case scenario is data from the final few patients is missing. There is provision in the new FDA guidance on clinical trials and covid to take account for that. The remaining data analysis is in the hands of private companies like Veristat, independent statistical analysis people and Antibe. I imagine all that data collation and number crunching can be done remotely. 

No need for there to be hold-ups at this stage. While there are no updates or announcements the best assumption is that they are still working to the same timetable announced in the last update. Maybe we get an update on the timing of the data release towards the end of this week or next week, maybe it comes earlier, who knows on the exact timing.

 

mtlmoneyman wrote: We might have to wait a bit longer for the test results -
the health care system is overwhelemd with work -
we should see some kind of announcement shortly on this -
stay safe 
 

 

 



Bullboard Posts